Video Experimental Relacionado
Updated: Jun 15, 2026
07:38
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
Dinámica de la estrectura y pronóstico durante la terapia biológica en la enfermedad ileal de Crohn: una cohorte del
Kento Takenaka1, Ami Kawamoto2, Shuji Hibiya2
1Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
Inflammatory bowel diseases
|February 10, 2026
Resumen
Las terapias biológicas muestran una eficacia similar a corto plazo para las estenosis ileal de la enfermedad de Crohn (EC). Los estrechamientos persistentes a los seis meses, particularmente en el íleon no terminal, predicen peores resultados, incluida la hospitalización y la cirugía.
Área de la Ciencia:
- Gastroenterología y Gastroenterología.
- Enfermedades Inflamatorias del Intestino Investigación de la Enfermedad del Intestino.
- Terapéutica Clínica y Terapéutica Clínica.
Sus antecedentes:
- Las estenosis ileal son una complicación común de la enfermedad de Crohn (EC).
- Existen datos limitados sobre la respuesta a corto plazo de estas estruturas a las terapias biológicas.
- Los ensayos clínicos actuales a menudo priorizan la curación de la mucosa por encima de la evaluación de la estenosis.
Objetivo del estudio:
- Para cuantificar los cambios a corto plazo en las estenosis ileal en pacientes con enfermedad de Crohn tratados con productos biológicos.
- Para evaluar la relevancia pronóstica del estado de estricción después de seis meses de terapia biológica.
- Para comparar la dinámica de las restricciones en diferentes clases de fármacos biológicos.
Principales métodos:
- Análisis post hoc de una cohorte prospectiva de 170 pacientes con CD.
- Pacientes que iniciaron o cambiaron la terapia biológica (factor de necrosis antitumoral [TNF], ustekinumab [UST] o vedolizumab [VDZ]).
- La evaluación endoscópica al inicio y a los seis meses evaluó la resolución o progresión de la estenosis; los análisis de tiempo hasta el evento para la hospitalización / cirugía fueron resultados secundarios.
Principales resultados:
- A los seis meses, el 30,9% de los estreñimientos se resolvieron y el 15,7% progresaron.
- No se observaron diferencias significativas en la dinámica de la estricción entre los agentes anti-TNF, UST y VDZ.
- Los estrechamientos presentes a los seis meses, especialmente en el íleon no terminal, se asociaron con un mayor riesgo de hospitalización y cirugía.
Conclusiones:
- El estado de estricción a los seis meses, particularmente la participación ileal no terminal, es un indicador pronóstico significativo en la CD.
- La elección del agente biológico no debe basarse únicamente en la presencia de estenosis, ya que las dinámicas son similares en todas las clases.
- La actividad clínica, bioquímica y endoscópica generalmente mejoró durante el período de estudio.
Videos de Conceptos Relacionados
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...